The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease (MASLD/MAFLD) in adults with components of metabolic syndrome. Up to 10,000 participants aged ≥18 years with overweight, obesity, or metabolic risk factors will undergo standardized screening including a health questionnaire, anthropometric measurements, blood pressure assessment, laboratory testing, and liver ultrasound. The study aims to generate a comprehensive metabolic-hepatic dataset integrating clinical, laboratory, imaging, and lifestyle data. Collected data will be used to identify metabolic and behavioral risk factors for MASLD, characterize disease phenotypes, and support the development of predictive models. The ENDOCARE-SCREEN study will also serve as a qualification platform for selecting eligible participants for a subsequent interventional randomized controlled trial (ENDOCARE-SUPPORT). The study involves minimal risk procedures routinely used in clinical practice and follows ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.
Metabolic dysfunction-associated steatotic liver disease (MASLD/MAFLD) is currently the most common chronic liver disease worldwide and represents the hepatic manifestation of metabolic syndrome. Despite its high prevalence, large-scale standardized screening data integrating metabolic, imaging, and lifestyle factors are limited in Central and Eastern Europe. The ENDOCARE-SCREEN study addresses this gap by implementing a structured screening program in a real-world ambulatory population. The study collects detailed sociodemographic, metabolic, behavioral, and imaging data, allowing for comprehensive phenotyping of liver dysfunction in individuals with metabolic risk. In addition to epidemiological objectives, the study assesses participants' readiness for lifestyle modification and digital health tools, supporting the future implementation of personalized, technology-assisted interventions. Data generated in ENDOCARE-SCREEN will inform clinical decision-making, public health strategies, and the design of subsequent interventional studies.
Study Type
OBSERVATIONAL
Enrollment
10,000
ENDOCARE
Wroclaw, Poland
Prevalence of MAFLD/MASLD
Proportion of participants meeting MAFLD/MASLD criteria according to current definitions
Time frame: Baseline (single screening visit)
Distribution of hepatic steatosis severity on liver ultrasound
Ultrasound steatosis grade (0-3): mild (1), moderate (2), severe (3).
Time frame: Baseline (single screening visit)
Association between MAFLD and metabolic syndrome burden
Relationship between MAFLD status and number of metabolic syndrome components
Time frame: Baseline
Association between MAFLD and anthropometric parameters
Relationship between MAFLD and body mass index (BMI) and waist circumference
Time frame: Baseline
Association between MAFLD and glycemic status
Relationship between MAFLD and diabetes/prediabetes markers (e.g., fasting glucose/HbA1c as collected)
Time frame: Baseline
Association between MAFLD and lipid profile
Relationship between MAFLD and lipid parameters as collected in routine labs
Time frame: Baseline
Independent predictors of MAFLD and moderate-to-severe steatosis
Multivariable models (e.g., logistic regression) identifying predictors of MAFLD and moderate-to-severe steatosis
Time frame: Baseline
Previously undiagnosed MAFLD/liver disease
Proportion of participants with newly identified MAFLD/liver abnormalities during screening
Time frame: Baseline
Eligibility yield for the interventional stage
Proportion of screened participants meeting pre-defined qualification criteria for the second stage (ENDOCARE-SUPPORT)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.